Entresto 97/103mg Dosing: When to Initiate at This Dose
Entresto 97/103 mg twice daily is the target maintenance dose, not a starting dose—initiate at 49/51 mg twice daily in most patients, then titrate up to 97/103 mg after 2-4 weeks as tolerated. 1
Standard Initiation Protocol
For most patients with HFrEF:
- Start at 49/51 mg twice daily
- Double the dose after 2-4 weeks to reach the target of 97/103 mg twice daily 2, 1
- This applies to patients already on ACE inhibitors or ARBs at moderate-to-high doses (equivalent to >10 mg enalapril daily or >160 mg valsartan daily) 2
When to Start at Lower Doses (NOT 97/103 mg)
Start at 24/26 mg twice daily in these specific situations:
- Severe renal impairment (eGFR <30 mL/min/1.73 m²) 2
- Moderate hepatic impairment (Child-Pugh B) 2
- Patients not currently on ACE inhibitor/ARB or on low doses (equivalent to <10 mg enalapril daily) 1
- Systolic blood pressure <100 mmHg or concerns about hypotension 2, 3
Then titrate upward every 2-4 weeks toward the 97/103 mg target dose 1.
Direct-to-ARNI Approach
Recent evidence supports initiating Entresto without prior ACE inhibitor/ARB exposure in de novo heart failure, with comparable safety and potentially superior outcomes 2, 4. However, these patients should still start at lower doses (24/26 mg or 49/51 mg depending on blood pressure and renal function) and titrate up.
Critical Safety Requirements Before ANY Dose
- 36-hour washout from ACE inhibitors (angioedema risk) 2, 1
- No history of angioedema with ACE inhibitors or ARBs 2
- Potassium <5.0-5.2 mEq/L 2, 5
- Hemodynamic stability (not acutely decompensated) 2, 3
Monitoring During Titration to 97/103 mg
After each dose increase, monitor:
- Blood pressure (watch for symptomatic hypotension, though asymptomatic low BP doesn't require dose reduction if patient is stable) 3
- Renal function and electrolytes within 1-2 weeks 2
- Volume status (may need diuretic adjustment) 2, 3
A decrease in eGFR >30% or potassium >5.5 mEq/L should prompt dose reduction, though mild initial eGFR decline doesn't predict poor long-term outcomes 2.
Target Dose Achievement
The 97/103 mg twice daily dose is the goal for maximizing mortality and morbidity benefits 6, 7. In clinical trials, mean achieved doses were 182/193 mg total daily (approximately 91/96.5 mg twice daily) 7. While 72-82% of patients can achieve target dose with gradual titration, even patients with baseline SBP 100-110 mmHg can reach target in ~73% of cases with careful 6-week titration 8.
Key principle: Start low based on patient-specific factors, titrate systematically every 2-4 weeks, and aim for 97/103 mg twice daily as the therapeutic target—don't start at this dose except in rare circumstances where a patient is already on very high-dose ARB and has excellent blood pressure/renal function tolerance.